Showing 21 - 30 of 36,475
The National Institute for Health and Clinical Excellence (NICE) recently issued updated guidance on the use of cholinesterase inhibitors in the treatment of Alzheimer's disease. NICE initially recommended that cholinesterase inhibitors no longer be used, but final guidance restricted treatment...
Persistent link: https://www.econbiz.de/10005243114
Objective: Influenza vaccination rates remain far below national goals in the US. Expanding influenza vaccination in non-traditional settings such as worksites and pharmacies may be a way to enhance vaccination coverage for adults, but scant data exist on the cost effectiveness of this strategy....
Persistent link: https://www.econbiz.de/10005243115
DOI: 10.2165/0019053-200826120-00008
Persistent link: https://www.econbiz.de/10005243120
Background: In 2005, a new technology appraisal process (the Single Technology Appraisal [STA]) was implemented by the National Institute for Health and Clinical Excellence (NICE), an independent agency that provides guidance to the UK NHS on the use of technology. The objective of STAs was to...
Persistent link: https://www.econbiz.de/10005243121
The optimal adjuvant hormonal strategy in post-menopausal women with early breast cancer is a subject of ongoing debate. Aromatase inhibitors (AIs) have been successfully evaluated in clinical trials that have compared them with a standard treatment of 5 years of tamoxifen. However, several...
Persistent link: https://www.econbiz.de/10005243123
Objective: To estimate the pharmacoeconomic impact for the French Social Security System of preventing recurrent acute rhinopharyngitis (RARP) in at-risk children with OM-85 BV, an immunostimulating agent indicated for the prevention of recurrences. Design: A decision-analysis model. The...
Persistent link: https://www.econbiz.de/10005243125
Persistent link: https://www.econbiz.de/10005243128
We systematically reviewed published economic evaluations of systemic antifungal therapies and assessed their strengths and weaknesses. The study identified all economic evaluations published before May 2002 and critically appraised their methods using a published checklist. Over 1000 papers on...
Persistent link: https://www.econbiz.de/10005243130
The economic burden of influenza-related illness has been estimated to be $US71.3-166 billion in the US, the majority of which is attributable to indirect costs as a result of lost productivity. There are currently four antiviral drugs available for the treatment of influenza: two ion channel...
Persistent link: https://www.econbiz.de/10005243143
A systematic review of the literature was conducted to give an overview of economic evaluations of preventive interventions in type 2 diabetes mellitus. The interventions were sorted by type of preventive intervention (primary, secondary or tertiary) and by category (e.g. education, medication...
Persistent link: https://www.econbiz.de/10005243149